Company intelligence
ANEMOCYTE
Manufacturing Biotech Innovation
About ANEMOCYTE
Anemocyte is a leading Italian Biotech Manufacturing Organization (BMO) specializing in innovation, development, manufacturing, and analytical services for the Cell & Gene Therapy (CGT) and Nucleic Acids ecosystem. We bridge the gap between scientific innovation and clinical reality through cutting-edge platforms: 🔹 pDNA Platform: Expert manufacturing of Plasmid DNA (R&D, High-Quality, and GMP) for Viral Vectors and mRNA applications. We offer customized solutions and Off-the-Shelf pDNA products (including specialized LVV platforms) to streamline your supply chain and accelerate speed-to-clinic. 🔹 mRNA & AMCAP™ Technology: mRNA manufacturing for vaccines and therapeutic treatments. Our proprietary AMCAP™ (patent-pending) "One-Pot" synthesis technology delivers high-yield, superior Cap-1 mRNA with reduced complexity and costs. 🔹 AMClarity: Our specialized division for Visual Inspection Confidence. We provide precision-mimicking defective reference standards (defect kit) and GMP qualification services to ensure the highest quality for high-stakes life science products. Our Experience: • 25+ years of experience in the development and manufacturing (from R&D to GMP) of Cell and Gene Therapies and Nucleic Acids. • A client-centric approach: from custom projects to ready-to-use Off-the-shelf mRNA/pDNA and AMCAP™ IVT Kits, we provide the flexibility needed to scale your innovation. Empowering the future of medicine through biotech manufacturing innovation.
Verified activity
Signals from ANEMOCYTE
4 published signals
Partnerships
ANEMOCYTE is a co-founding member of the European RNA Alliance (ERA)
Reported by ANEMOCYTE
Presence & Recognition
ANEMOCYTE is attending the ISCTAsia 2026 conference in Singapore.
Reported by ANEMOCYTE
Presence & Recognition
ANEMOCYTE is on site at ISCT Asia 2026 in Singapore to connect with the cell and gene therapy community and share expertise across plasmid DNA and mRNA manufacturing.
Reported by ANEMOCYTE
Presence & Recognition
ANEMOCYTE will attend the 3rd RNA Horizons Conference in Munich from September 16 to 18, 2026, with Massimo Carraro representing the company.
Reported by ANEMOCYTE